Callos Andrew 4

What Happened
Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, sold 7,449 shares of CYTK in an open-market transaction on 2026-04-15 at $66.02 per share, for total gross proceeds of $491,783. This was a sale (Code S) rather than a purchase; insider sales are often routine liquidity events and do not necessarily indicate a change in company fundamentals.

Key Details

• Transaction date: 2026-04-15
• Transaction type: Open-market sale (S)
• Shares sold: 7,449 @ $66.02 per share
• Total proceeds: $491,783
• Shares owned after transaction: Not disclosed in the filing
• 10b5-1 / plan footnotes: No plan or special footnotes disclosed in the report
• Filing timeliness: Reported and filed for period 2026-04-15 (no late filing indicated)
• SEC accession #: 0001061983-26-000036

Context
Sales by executives can reflect personal financial planning (taxes, diversification, etc.) and are generally less informative than purchases for gauging insider conviction. This filing shows a straightforward open-market disposition with no option exercise, gift, or complex derivative involved.